tbuckley/cabot-search huggingface dataset:
Abstract 3473: Intra-person and inter-person biomarker variation for modeling longitudinal values of ovarian cancer early detection biomarkers.
Authors: Archana Raamanathan, Zhen Lu, Robert C. Bast, Steven J. Skates
Journal: Cancer Research (2013)

Abstract In 2012, an estimated 22,280 women will be diagnosed with ovarian cancer in the United States and 15,500 women will die from this disease. Though localized ovarian cancers have a survival rate of 92%, only 15-20% of ovarian cancers are detected at this stage. Developing an effective strategy for early detection could reduce mortality. While individual values of CA125 are neither sufficiently sensitive nor specific for early detection, monitoring CA125 over time shows greater specificity. The risk of ovarian cancer algorithm, ROCA, analyzes the trend of annual values for CA125, utilizing each woman's own baseline to refer a small fraction (&amp;lt;1-2%) of women to transvaginal sonography. Using this strategy, no more than three operations are required for each case of ovarian cancer detected. Use of multiple biomarkers might increase sensitivity for preclinical disease. Based on a multiplex assay of 96 biomarkers, a four biomarker panel was identified of CA125, HE4, MMP-7 and CA 72-4 with greater sensitivity than CA125 alone. To estimate the utility of these biomarkers for longitudinal screening, we assessed five annual longitudinal control serum samples from 200 women who did not develop ovarian cancer from the MDACC SPORE normal risk ovarian cancer screening study (NROSS). Utilizing WinBUGS, the inter-person and intra-person CVs were evaluated. Upon log transformation for CA125, HE4 and MMP-7 and log(log()+1) transformation for CA72-4, both the inter-person and intra-person CVs follow a log-normal distribution. The median inter-person CVs for CA125, HE4, MMP-7 and CA 72-4 were 49%, 20%, 35% and 84% respectively and the median intra-person CVs were 15%, 25%, 21% and 21% respectively. The ratios of intra-person CVs to inter-person CVs derived for CA125, HE4, MMP-7 and log(CA 72-4) were 0.31, 1.25, 0.6 and 0.31. We anticipate that the lower the ratio, the higher the contribution of each individual marker to early detection during longitudinal measurements. The intra-person CV's should permit development of a multi-marker algorithm. Assessment of longitudinal samples derived from 50 cases of preclinical ovarian cancer and 10 controls per case (UKCTOCS trial) are underway in order to establish such a longitudinal multi-marker algorithm for assessment of ovarian cancer risk. Citation Format: Archana Raamanathan, Zhen Lu, Robert C. Bast, Steven J. Skates. Intra-person and inter-person biomarker variation for modeling longitudinal values of ovarian cancer early detection biomarkers. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3473. doi:10.1158/1538-7445.AM2013-3473
SAT0238 Clinical significance of hemolytic anemia in a cohort of 1000 brazilian patients with systemic lupus erythematosus. results from a single center
Authors: G. Costallat, S. Appenzeller, L.T.L. Costallat
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Systemic lupus can affect multiple organs and it is associated with significant morbidity and mortality. Hematological manifestations in lupus are common and autoimmune hemolytic anemia (AHA) is a SLE classification criterion as well thrombocytopenia and leucopenia. It's usually related with the more severe cases of SLE. <h3>Objectives</h3> To analyze the frequency of hemolytic anemia in a Brazilian cohort of 1000 patients with SLE and the clinic manifestations that might be related to hemolytic anemia as their clinic evolution <h3>Methods</h3> We reviewed retrospectively all cases of AHA from our lupus cohort of 1000 cases followed up between 1974 and 2011. Clinical data used in this study were extracted from the medical records of Hospital das Clínicas of State University of Campinas, Brazil. Hemolytic anemia was defined according to the American College of Rheumatology criteria for the classification of SLE and was not considered when secondary to drugs. We classified AHA in 75 patients according to severity in mild to moderate (women's hemoglobin 7 g/dL - 11 g/dL and men's hemoglobin 7 g/dL – 13 g/dL) or severe (≤7 g/dL); time of occurrence when at onset of SLE (first 6 months) or during the course of SLE (after 6 months) and frequency: a single episode or recurrent episodes. We compared patients with and without hemolytic anemia concerning to different clinical manifestations of the disease <h3>Results</h3> Hemolytic anemia was present in 112 patients (11,2%) of all cases of SLE. The mean age of the patients was 27.13 years.There were 105 women and 7 men; 77 Caucasian and 35 non -Caucasian. Lupus patients with hemolytic anemia had more pleuritis (P=0,029), nephritis (P=0,012), leucopenia (P=0,001) and thrombocytopenia (P&lt;0.001) and anti-dsDNA antibodies (P=0,008). Patients with Hemolytic anemia died more than patients without this manifestation (P=0,009). In 75 patients we observed AHA as a single episode in 64 (85%), recurrent episodes in 11 (15%) and at onset of SLE in 53 cases (71%) and in the evolution in 22 (29%). AHA was mild to moderate in 38,5% and severe in 61,5% <h3>Conclusions</h3> Hemolytic anemia occurred in 11,2% of SLE, usually severe, at the onset of the disease and in a single episode. Pleuritis, nephritis, other cytopenias and Anti-DNA antibodies were strongly related to AHA. The higher death rate (18%) when compared to the patients without AHA (10.4%) was assigned to the multi systemic involvement, with high percentage of nephritis and other severe manifestations. <h3>Disclosure of Interest</h3> G. Costallat Grant/Research support from: FAPSEP 2011/02907-8, S. Appenzeller Grant/Research support from: FAPESP 2008/02917-0; Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/2009-4), L. Costallat: None Declared
AB0733 Which Chronic Back Pain (CBP) Characteristics Are Associated with A Positive HLA-B27 in Patients with Suspected Axial Spondyloarthritis (AXSPA)? Results from the Esperanza Cohort: Table 1
Authors: V. Navarro-Compán, J.J. Aznar, L.F. Linares, E. Collantes-Estevez, P. Zarco
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> CBP is nowadays the starting point for the ASAS classification criteria for axSpA. Later, two possible entry criteria based on complementary examinations (HLA-B27 and imaging) are considered. However, CBP is a very prevalent symptom so it is necessary to identify those characteristics more likely resulting in a positive complementary test. <h3>Objectives</h3> To evaluate which inflammatory characteristics of CBP are associated with the presence of HLA-B27 in patients with suspected axSpA. <h3>Methods</h3> Baseline dataset from the EsPeranza cohort (&lt;45 yrs, symptoms duration 3-24 months and with inflammatory back pain -IBP- or asymmetrical arthritis or spinal/joint pain plus ≥1 SpA features) was used. Data from 653 patients with axial symptoms and HLA-B27 assessed were analysed. Odds ratio were estimated for the association between IBP characteristics (morning stiffness, improve with exercise and not with rest, alternating buttock pain, insidious onset, awakening at 2nd half of night and good response to NSAIDs) and their different combinations with a positive HLA-B27 (local lab test). <h3>Results</h3> A total of 270 (41%) patients were HLA-B27+. Table shows results for the association between individual and combined IBP characteristics with HLA-B27+. Awakening at 2nd half of night (OR=1.53;p&lt;0.05) and response to NSAID (OR=1.46; p&lt;0.05) were the only characteristics independently associated with HLA-B27+ but had lower specificity than the existing criteria combining several characteristics. The addition of these two characteristics to these criteria just improved their specificity slightly. Among the existing criteria to define IBP, the ASAS criteria were the most strongly associated with HLA-B27 and the most specific. <h3>Conclusions</h3> Awakening at second half of night and good response to NSAIDs are both related to positive HLA-B27 in patients with suspected axSpA although they are less specific than the existing criteria to define IBP. The most specific criteria for a positive HLA-B27 are the ASAS criteria. <h3>Acknowledgements</h3> The EsPeranza Program has been supported by an unrestricted grant from Pfizer <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1814
Breast Density, Ki67 and Larger Extensions of Breast Cancer.
Authors: C. Mameri, C. Mameri, C. Mameri, L. Sobral, D. Chambo, H. Totola, J. Mameri Filho
Journal: Cancer Research (2009)

Abstract Background: Studying breast cancer, our data has demonstrated higher occurrence of large extensions and/or multiple synchronic malignant lesions in dense breasts. Following this investigation, we decided to correlate breast density with Ki67 on tumor specimens and disease extent on MRI. Methods: From August 2005 to April 2009, 193 consecutive patients diagnosed with breast cancer were evaluated about number and size of breast malignant lesions, about fibroglandular (FG) density on Mammography and about proliferation marker on immunohistochemistry of tumor cells. Fibroglandular density was classified using criteria: &amp;lt;50%; &amp;gt;50%. All patients had evaluation of hormonal receptors (estrogen and progesterone), HER2/neu and Ki67 on immunohistochemistry of tumor blocks. They were also submitted to bilateral breast MRI in 1.5 T Excite/GE equipment, 5 sequences FSPGR (90 seconds each, 1 preinjection, 4 postinjection of gadolinium 0.16 mM/kg, 3.5/0 thickness) to evaluate size of primary lesion and presence of additional malignant foci. Additional findings were submitted to pathological examination (core or excisional biopsy). Results: Among 193 patients, 66 (34%) presented FG density &amp;lt;50% and 127 (66%) had FG density &amp;gt;50%. Eighty one patients (42%) presented large single tumor (35 cases) and/or multiple synchronic malignant lesions (46 cases), which 16/81 (19%) had FG density &amp;lt;50% and 65/81 (81%) had FB density &amp;gt;50%. In 112/193 patients (58%) with small single tumor on MRI, 66 (59%) had density &amp;gt;50%. Expression of Ki67 was 30% positive or higher in 17/66 patients (25,7%) with FG density &amp;lt;50% and in 70/127 patients (55%) with FB density &amp;gt;50%. Correlation between high expression of Ki67 (30% or higher) and extent was significant for patients with large single tumor (17/35=48,5%), but not for patients with multiple synchronic lesions (11/46=24%). Expression of Ki67 was 30% positive or higher associated with HER2 overexpression (3+) or with triple negative tumors in 95% of both conditions (multiple synchronic or larger single tumors). Conclusions: This study demonstrated that dense breasts are associated with larger extensions of breast cancer and suggests that FB density can be correlated to higher expressions of Ki67 on immunohistochemistry, especially in single tumors. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6043.
Accuracy of DCE – MRI in predicting response in patients treated with taxane based neoadjuvant chemotherapy.
Authors: V Garimella, D Elfadl, MB Elahi, TK Mahapatra, PL McManus, A Chaturvedi, S Upadhyay, P O'Neil, LW Turnbull, PJ Drew
Journal: Cancer Research (2009)

Abstract Abstract #5120 Background: Neoadjuvant chemotherapy for locally advanced breast cancer is an established treatment option. Several studies have shown DCE-MRI scanning to be the most accurate investigation to assess response to EC chemotherapy. Recent trials have shown that addition of Taxanes increases the overall response rate and the rate of breast conserving surgery. Taxanes act by inhibiting angiogenesis in the tumour and this could potentially affect the quality of the post treatment scan images as DCE-MR scan and cause inappropriate decisions regarding the required surgery.&amp;#x2028; Aim: To compare the accuracy of DCE-MR scan in identifying residual disease in patients treated with FEC (Fluoro uracil, Epirubicin, Cyclophosphamide) vs EC (Epirubicin, Cyclophosphamide) followed by Taxane.&amp;#x2028; Methods: Patients treated with primary chemotherapy who subsequently underwent breast conserving surgery were identified from a prospectively maintained database. Clinical details including chemotherapy regimes, pre and post chemotherapy MRI data, number of surgical procedures and histological parameters of the excised specimen were obtained.&amp;#x2028; Results: A total of 121 patients treated with primary chemotherapy were identified. Of these, 76 were treated with FEC or EC based chemotherapy and 45 were treated with EC+Taxane. DCE-MRI was significantly less accurate (p&amp;lt;0.05) when predicting the size of residual disease in the Taxane group.&amp;#x2028; &amp;#x2028; Conclusion: DCE MR scan is not as accurate for quantifying size of residual disease in patients treated with taxane when compared with patients treated with traditional FEC/EC based primary chemotherapy. This should be considered when planning surgery after neoadjuvant therapy. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5120.
P2-03-05: Attenuation of TGF-beta Signaling Suppresses Premature Senescence in a p21-Dependent Manner and Promotes Oncogenic ras-Mediated Metastatic Transformation in hTERT-Immortalized Basal-Like Human Mammary Epithelial Cells.
Authors: S Lin, J Yang, AG Elkahloun, A Bandyopadhyay, L Wang, JE Cornell, I-T Yeh, JK Agyin, L-Z Sun
Journal: Cancer Research (2011)

Abstract Triple negative, basal-like breast cancer is highly aggressive and has a poor prognosis. The molecular mechanisms that drive its progression are elusive and no molecular target has been identified for its prevention or treatment. Here, we demonstrate that triple negative human breast cancer cells and clinical samples show an attenuated transforming growth factor-beta (TGF-β) signaling. Therefore, we developed a series of isogenic basal-like human mammary epithelial cells (HMECs) with altered TGF-β sensitivity and different malignancy, resembling a full spectrum of basal-like breast carcinogenesis, and determined the molecular mechanisms that contribute to oncogene-induced transformation of basal-like HMECs when TGF-β signaling is attenuated. We found that expression of a dominant-negative RII (DNRII) receptor of TGF-β abrogated autocrine TGF-β signaling in telomerase-immortalized HMECs and suppressed H-ras-V12-induced senescence-like growth arrest (SLGA). Furthermore, co-expression of DNRII and H-ras-V12 rendered HMECs to become highly tumorigenic and metastatic in vivo in comparison with H-ras-V12-transformed HMECs that spontaneously escaped H-ras-V12-induced SLGA. By using microarray analysis, we found that p21 is the major player mediating Ras-induce SLGA and attenuated or loss of p21 expression contributed to the escape from SLGA when autocrine TGF-β signaling is blocked in HMECs. Furthermore, knockdown of p21 also suppressed H-ras-V12-induced SLGA. Our results identifies that autocrine TGF-β signaling is an integral part of cellular antitransformation network by suppressing the expression of a host of genes including p21-regulated genes that mediate oncogene-induced transformation in basal-like breast cancer. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-03-05.
Lung Scintigraphy in Post-Lung Transplant Bronchial Stenosis
Authors: BRUCE ZUKERBERG, MANISH GOYAL, PINAR OZGEN, MARK W. GRAVES, ALICE SCHEFF
Journal: Clinical Nuclear Medicine (1996)

Bronchial stenosis due to anastomotic stricture is a known complication of lung transplant surgery. Computed tomography and bronchoscopy are frequently employed in the evaluation of this complication. The role of lung scintigraphy is not well defined. The authors report a case of a 59-year-old man who underwent bilateral lung transplantation for chronic obstructive pulmonary disease. Right bronchial stenosis subsequently developed at the site of the anastomosis. CT scan and bronchoscopy demonstrated severe right bronchial stenosis and marked thickening of the bronchial mucosa. Correlative ventilation/perfusion scanning showed almost complete absence of ventilation and perfusion in this lung.
Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
Authors: Rudolph M. Navari, Rick R. Reinhardt, Richard J. Gralla, Mark G. Kris, Paul J. Hesketh, Ali Khojasteh, Hedy Kindler, Thomas H. Grote, Kelly Pendergrass, Steven M. Grunberg, Alexandra D. Carides, Barry J. Gertz
Journal: New England Journal of Medicine (1999)

The localization of substance P in brain-stem regions associated with vomiting, and the results of studies in ferrets, led us to postulate that a neurokinin-1-receptor antagonist would be an antiemetic in patients receiving anticancer chemotherapy.In a multicenter, double-blind, placebo-controlled trial involving 159 patients who had not previously received cisplatin, we evaluated the prevention of acute emesis (occurring within 24 hours) and delayed emesis (on days 2 to 5) after a single dose of cisplatin therapy (70 mg or more per square meter of body-surface area). Before receiving cisplatin, all the patients received granisetron (10 microg per kilogram of body weight intravenously) and dexamethasone (20 mg orally). The patients were randomly assigned to one of three treatments in addition to granisetron and dexamethasone: 400 mg of an oral trisubstituted morpholine acetal (also known as L-754,030) before cisplatin and 300 mg on days 2 to 5 (group 1), 400 mg of L-754,030 before cisplatin and placebo on days 2 to 5 (group 2), or placebo before cisplatin and placebo on days 2 to 5 (group 3). Additional medication was available at any time to treat occurrences of vomiting or nausea.In the acute-emesis phase, 93 percent of the patients in groups 1 and 2 combined and 67 percent of those in group 3 had no vomiting (P<0.001). In the delayed-emesis phase, 82 percent of the patients in group 1, 78 percent of those in group 2, and 33 percent of those in group 3 had no vomiting (P<0.001 for the comparison between group 1 or 2 and group 3). The median nausea score in the delayed-emesis phase was significantly lower in group 1 than in group 3 (P=0.003). No serious adverse events were attributed to L-754,030.The neurokinin-1-receptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin. Moreover, combining L-754,030 with granisetron plus dexamethasone improves the prevention of acute emesis.
Abstract B23: Dominant stablized ß-catenin induces adenomyosis formation and ablation of <i>Mig-6</i> accelerates progress of adenomyosis formation
Authors: Jung-Ho Shin, Tae Hoon Kim, Michael J. Large, Sung Nam Cho, Seo Jin Oh, Jeong Mook Lim, Makoto M. Taketo, Russell R. Broaddus, Jae-Wook Jeong
Journal: Clinical Cancer Research (2010)

Adenomyosis is a common gynecological disorder defined by the presence of endometrial glands and stroma within the myometrium. Despite its frequent occurrence, the precise etiology of adenomyosis is still unknown, although it has often been associated with endometrioid adenocarcinoma. β-catenin abnormalities are common in endometrioid type endometrial carcinomas. The expression of the dominant stabilized β-catenin in the murine uterus (PRcre/+ Ctnnb1f(ex3)/+) resulted in endometrial glandular hyperplasia. In addition to the glandular hyperplasia phenotype, uteri of PRcre/+ Ctnnb1f(ex3)/+ mice exhibited an abnormal myometrial structure and proceed to develop adenomyosis. Ablation of Mig-6 in the murine uterus (PRcre/+ Mig-6f/f) leads to the development of endometrial hyperplasia and estrogen-induced endometrial cancer. Concomitant stabilization of β -catenin and ablation of Mig-6 dramatically accelerated the development of adenomyosis and glandular hyperplasia compared to stablizing β-catenin alone. The adenomyosis phenotype of ovariectomized Pffre/+ Ctnnb1f<ex3)/+ and PRcre/+ Ctnnb1f(ex3)/+Mig-6f/f mice manifests in the presence of E2 and P4, but not, however, in the absence of ovarian hormones. Importantly, increased nuclear β-catenin expression and decreased MIG-6 expression was observed in women with adenomyosis, providing compelling support for and implicating an important role of β-catenin and MIG-6 in the etiology of adenomyosis in both humans and mice. We have demonstrated that abnormal activation of β-catenin induces adenomyosis formation and ablation of Mig-6 accelerates the progress of adenomyosis formation in the murine uterus. These mouse models are useful and allow us to investigate in detail the initiation and progression of adenomyosis because they mimic several features of human adenomyosis.Citation Information: Clin Cancer Res 2010;16(14 Suppl):B23.
Film: The Messenger: The Story of Joan of Arc
Authors: S. A Spence
Journal: BMJ (1999)

Directed by Luc Besson Gaumont Pictures/Columbia Tristar, on general release in north America Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> “When I was thirteen years old, I had a voice from God to help me govern my conduct… The first time I was very fearful. And came this voice, about the hour of noon, in the summer-time, in my father's garden… I heard the voice on the right-hand side, towards the church; and rarely do I hear it without a brightness. This brightness comes from the same side as the voice is heard. It is usually a great light… This voice was sent to me by God and, after I had thrice heard this voice, I knew that it was the voice of an angel. This voice has always guided me well and I have … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
1377 HYPOTHYROIDISM IS NOT ASSOCIATED WITH SPECIFIC HISTOLOGICAL FEATURES OR SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE
Authors: Y. Yilmaz, T. Ayyildiz, Y. Colak, E. Senates, M. Arabul, B. Unsal, I. Tuncer, E. Dolar
Journal: Journal of Hepatology (2013)
AB1013 Systemic Sclerosis and Myositis Extractable Nuclear Antigen (ENA) Analysis: Profile of A Cohort of Subjects with Isolated Raynaud's Phenomenon
Authors: R. Gualtierotti, F. Ingegnoli, T. Schioppo, C. Lubatti, S. Zeni, C. Mastaglio, V. Galbiati, C. Grossi, M.O. Borghi, L. Castelnovo, P.L. Meroni
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Raynaud9s phenomenon (RP) may predate an overt Connective Tissue Disease (CTD) of the "Scleroderma spectrum" such as Systemic sclerosis (SSc). The predictive role of auto-antibodies (auto-Abs) such as ANA for the development of a CTD in patients with isolated RP (i.e. with no other signs or symptoms of CTD) is well known, whereas data regarding the prevalence of anti-ENA in such patients are lacking. <h3>Objectives</h3> Our aim was to evaluate the profile of anti-ENA in patients with isolated RP. <h3>Methods</h3> Sera were analyzed for anti-ENA by EUROLINE "Scleroderma profile" (antigens: Scl70, CENP A, CENP B, RP11, RP155, fibrillarin (Fib), NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR, Ro-52) and "Myosites profile" (antigens: Mi-2, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52) [EUROIMMUN AG Leuback, Germany]. <h3>Results</h3> A total of 115 adults (105 females and 10 males) with isolated RP were enrolled in two Italian Rheumatology Centers (G. Pini Institute, Milan and Moriggia-Pelascini Hospital, Gravedona) from March 2011 to September 2013. Forty-four of 115 (38.0%) subjects were positive for at least one anti-ENA; 71 out of 110 (61.7%) were negative both for Scleroderma and Myosites profiles (see table 1 and 2). <h3>Conclusions</h3> Up to 38% of RP subjects were positive for at least one anti-ENA. The detection of anti-ENA since the first Rheumatologic evaluation may aid the specialist in achieving an earlier diagnosis. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5955